venBio Global Strategic Fund III, L.P. 13D and 13G filings for Artiva Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 4:44 pm Sale | 2025-03-31 | 13G | Artiva Biotherapeutics, Inc. ARTV | venBio Global Strategic Fund III, L.P. | 1,198,975 4.900% | -320,996 (-21.12%) | Filing |
| 2024-11-14 4:56 pm Sale | 2024-09-30 | 13G | Artiva Biotherapeutics, Inc. ARTV | venBio Global Strategic Fund III, L.P. | 1,519,971 6.300% | -298,624 (-16.42%) | Filing |
| 2024-08-01 7:00 pm Purchase | 2024-07-22 | 13G | Artiva Biotherapeutics, Inc. ARTV | venBio Global Strategic Fund III, L.P. | 1,818,595 7.800% | 1,818,595 (New Position) | Filing |